- Home
- NU vs SIGA Comparison
NU vs SIGA Comparison
Compare NU & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$6.27
Company Overview
Basic Information| Metric | NU | SIGA |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.0B | 462.6M |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | NU | SIGA |
|---|---|---|
| Price | $16.76 | $6.27 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $17.60 | N/A |
| AVG Volume (30 Days) | ★ 36.2M | 327.3K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 9.57% |
| EPS Growth | ★ 41.55 | N/A |
| EPS | 0.52 | ★ 1.03 |
| Revenue | ★ $6,360,698,000.00 | $172,249,641.00 |
| Revenue This Year | $172.18 | N/A |
| Revenue Next Year | $24.47 | $132.36 |
| P/E Ratio | $32.45 | ★ $6.09 |
| Revenue Growth | ★ 20.40 | N/A |
| 52 Week Low | $9.01 | $4.95 |
| 52 Week High | $17.84 | $9.62 |
Technical Indicators
Market Signals| Indicator | NU | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 44.44 |
| Support Level | $15.59 | $6.20 |
| Resistance Level | $16.83 | $6.45 |
| Average True Range (ATR) | 0.42 | 0.17 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 54.44 | 33.73 |
Price Performance
Historical Comparison NU
SIGA
About NU Nu Holdings Ltd.
Nu Holdings Ltd provides digital banking services. It offers several financial services such as Credit cards, Personal accounts, Investments, Personal Loans, Insurance, Mobile payments, Business Accounts, and Rewards. The company earns the majority of its revenue in Brazil.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.